Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2)
Authors:
- Amir QaseemAQAmir Qaseem
- Jennifer YostJYJennifer Yost
- George M. AbrahamGAGeorge M. Abraham
- Rebecca AndrewsRARebecca Andrews
- Janet A. JokelaJJJanet A. Jokela
- Matthew C. MillerMMMatthew C. Miller
- Population Health and Medical Science Committee of the American College of PhysiciansPPPopulation Health and Medical Science Committee of the American College of Physicians
- Adam J. ObleyAOAdam J. Obley
- Elie A. AklEAElie A. Akl
- Andrew DunnADAndrew Dunn
- Mary Ann ForcieaMFMary Ann Forciea
- 1 October 2023
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (10) , 1396-1404
Abstract
Evidence for the use of outpatient treatments in adults with confirmed COVID-19 continues to evolve with new data. This is version 2 of the American College of Physicians (ACP) living, rapid practice points focusing on 22 outpatient treatments for COVID-19, specifically addressing the dominant SARS-CoV-2 Omicron variant. The Population Health and Medical Science Committee (formerly the Scientific Medical Policy Committee) developed this version of the living, rapid practice points on the basis of a living, rapid review done by the ACP Center for Evidence Reviews at Cochrane Austria at the University for Continuing Education Krems (Danube University Krems). This topic will be maintained as living and rapid by continually monitoring and assessing the impact of new evidence. Consider molnupiravir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Consider nirmatrelvir-ritonavir combination therapy to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Do not use ivermectin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.Keywords
This publication has 18 references indexed in Scilit:
- Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phaseInternational Journal of Infectious Diseases, 2022
- Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational studyThe Lancet, 2022
- Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron SurgeNew England Journal of Medicine, 2022
- Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: a report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working GroupBMJ Open, 2021
- The Development of Living, Rapid Practice Points: Summary of Methods From the Scientific Medical Policy Committee of the American College of PhysiciansAnnals of Internal Medicine, 2021
- Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID)Engineering, 2020
- Core Outcomes Set for Trials in People With Coronavirus Disease 2019Critical Care Medicine, 2020
- A minimal common outcome measure set for COVID-19 clinical researchThe Lancet Infectious Diseases, 2020
- Disclosure of Interests and Management of Conflicts of Interest in Clinical Guidelines and Guidance Statements: Methods From the Clinical Guidelines Committee of the American College of PhysiciansAnnals of Internal Medicine, 2019
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011